The discounts for Abbvy's Linzess and Salix Pharma's Xifaxan are 75% and 63% below list, respectively. Though the price for Xifaxan is about the same as the CMS gross price in 2024. (5/5)

GSK's COPD inhaler Trelegy Ellipta's IRA price of $175 is about in line with prices in Canada, while the price for the two-drug version Breo Ellipta at $67 is about 1/3 the price in Canada. (4/5)

Cancer drugs are the priciest in the group. The $8650 price for Bristol Myers' Myeloma drug Pomalyst is 60% below list; 30% below the gross price paid in 2024.
It's not clear how the IRA discounts on Pfizer's Xtandi and Ibrance compare to the MFN prices because those have not been released. (3/5)

The MFN price for GLP-1s is $245 starting next year. The 2027 IRA price for Novo Nordisk's Ozempic is slightly more at $274. The discounts negotiated for Merck's Janumet and Boehrigner Ingelheim's Tradjenta are >80% below their list prices. (2/5)

GSK's COPD Ellipta inhalers were second in overall utilization to the GLP-1s, with 1.7 million Medicare members using the drugs, followed by ABBV's IBS treatment Linzess with 626K members.

Novo's drugs tallied $14.4 B in gross costs over a year ended 2024, but the most expensive drugs were the cancer meds like BMY's Miyeloma drug Pmalyst, with a list price of $21,700. PFE's breat cancer treatment Ibrance was second at with a list price of $15, 700.